leadf
logo-loader
RNS
viewe-Therapeutics PLC

e-Therapeutics plc - Expansion of Scientific Advisory Board

RNS Number : 2190A
e-Therapeutics plc
28 September 2020
 

28 September 2020

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

e-therapeutics strengthens Scientific Advisory Board

 

e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company"), today announces the expansion of its Scientific Advisory Board (SAB) with the appointment of Dr Bill Harte and Professor John Mattick.

 

The appointments follow the establishment of the SAB in May of 2020 with the initial appointment of Dr Paul Burke as Chair following the Company's expansion into RNA interference (RNAi) as a therapeutic modality to pursue drug discovery outcomes.

 

Dr Bill Harte is a pharmaceutical veteran and serial entrepreneur with more than 30 years in both research and executive positions. He currently serves as the Chief Translational Officer at the Case Western Reserve University School of Medicine advising and translating preclinical programs into patients. Previously, he held executive roles at Amgen, Bristol Myers Squibb, Visum Therapeutics and E3X Therapeutics. Dr Harte's broad experience spans computational chemistry, structural biology and modelling, medicinal chemistry, product development and portfolio prioritisation as well as CEO experience. Bill has also done extensive work with top-tier VC firms.

 

John Mattick is Professor of RNA Biology at UNSW Sydney, and one of the world's foremost experts in the field. He was previously the Chief Executive of Genomics England, Executive Director of the Garvan Institute of Medical Research in Sydney, Director of the Institute for Molecular Biology at the University of Queensland, and Director of the Australian Genome Research Facility. He has published over 300 scientific articles, which have been cited over 70,000 times. His awards include the International Union of Biochemistry and Molecular Biology Medal, the Australian Government Centenary Medal, the University of Texas MD Anderson Cancer Center Bertner Award for Distinguished Contributions to Cancer Research, and the Human Genome Organisation Chen Medal for Distinguished Achievement in Human Genetics and Genomic Research.

 

Dr Paul Burke, Chair of Scientific Advisory Board, commented:

 

"I am delighted to welcome Bill and John to the e-therapeutics Scientific Advisory Board. We believe that their high calibre experience and guidance will be of significant value as the Company progresses its strategy to achieve its future commercial goals."

 

Ali Mortazavi, Executive Chairman, said:

 

"We are honoured and excited to have convened such a distinguished Scientific Advisory Board. Paul, Bill and John all have considerable industry experience, and we look forward to their strategic advice and insight on transforming the drug discovery process as we continue to grow e-therapeutics whilst exploring new areas such as RNAi."

 

For further information, please contact:

 

e-therapeutics plc

Ali Mortazavi, Executive Chairman

Laura Roca-Alonso, Chief Business Officer

 

Tel: +44 (0)1993 883 125

www.etherapeutics.co.uk  

 

Numis Securities Limited

Freddie Barnfield/Duncan Monteith (Nominated Adviser) 

James Black (Corporate Broking)

 

Tel: +44 (0) 207 260 1000 

www.numis.com

 

FTI Consulting

Simon Conway/Stephanie Cuthbert

Tel: +44 (0) 203 727 1000

Email:  [email protected]

 

About e-therapeutics plc

 

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

 

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

 

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKZGZLRNNGGZM

Quick facts: e-Therapeutics PLC

Price: 14.375

Market: AIM
Market Cap: £60.24 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read